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Purpose.toevaluatetheoutcomeofpatientswithHodgkin’slymphomawhounderwentautologoustransplantationatKHCCbone
marrow transplant program. Patients and Methods. Over 6 years, 63 patients with relapsed or refractory Hodgkin’s lymphoma
underwent high dose chemotherapy followed by autologous transplant. There were 25.4% patients in complete remission
(CR), 71.4% with chemotherapy responsive disease at the time of transplant. Prior to conditioning regimen, 56% received two
chemotherapy lines, and, 44% received more than two lines. Results. The main outcomes of the study are the rate of complete
remission at day 100, overall survival (OS), relapse-free survival (RFS), The impact of the following variables on OS and RFS:
(a) disease status at the time of transplant, (b) number of chemotherapy lines prior to conditioning, (c) age group, (d) time of
relapse < or >12 months were investigated. The CR at day 100 was 57%. The median overall survival for the whole group was
40.6 months; the median RFS was 20 months. The only factor which signiﬁcantly impacts the study outcomes was the number of
chemotherapy lines prior to conditioning on OS in favor of patients received two lines. Conclusion. In our study only the number
of chemotherapy lines received before conditioning had statistically signiﬁcant impact on OS.
1.Introduction
Among patients with early-stage Hodgkin’s lymphoma (HL)
the rate of relapse ranges from 10 to 15% [1] and in patients
with advanced stage HL the relapse rate ranges from 30 to
40% [2–6]. In addition, approximately 10–15% of patients
experience progression of disease after an initial partial re-
sponse.
High-dose chemotherapy (HDCT) followed by hemato-
poieticstemcelltransplantationcanachievesustainedremis-
sioninpatientswithadvancedrefractoryorrecurrentHL[7–
14]. Several factors can predict survival and RFS after high-
dose chemotherapy and autologous transplant. One of these
factorsisthenumberofchemotherapylinespatientsreceived
priortotransplant[15–19].Anotherfactorwhichwasshown
in previous studies to predict the risk of relapse was the
disease status at the time of transplant, with superior out-
comes in patients who were in complete remission (CR), or
minimal residual disease in comparison to those with bulky
disease [14, 17, 20], and the last factor which was shown to
inﬂuence the outcome is the time to initial relapse (TTR)
>12 months versus <12 months which is measured from
the date of diagnosis to that of proven relapse [21]. At the
KingHusseinCancerCenter(KHCC)bonemarrowandstem
celltransplantationprogram,Amman,Jordan,weperformed
stem cell transplantation for 63 patients with HL between
the years 2003 and 2008. We report herein the outcome of
these patients. Since our program is combined for adult and2 ISRN Oncology
pediatric patients, our study includes, as one of its objectives,
the comparison between the two age groups in treatment
outcome. To our knowledge there is no data available on
the impact of age on transplantation outcome of HL. (Adult
patients at our center are deﬁned as 18 years or older.)
2. Patientsand Method
The outcome of sixty-three patients who underwent HSCT
at KHCC between January 2003 and December 2008 was
studied through retrospective chart review after obtaining
IRB approval.
The diagnosis was conﬁrmed for all patients at KHCC by
pathology review, and they all met the standard criteria to be
eligible for autologous transplant. We included all patients
who underwent transplant if all data required for the study
was available in their ﬁles.
We reviewed 70 ﬁles for patients with relapsed/refractory
HL who underwent transplant at KHCC during the study
period. Data about disease status at the time of transplant,
number of chemotherapy lines received before transplant,
evaluation at day 100, vital status, and disease status at last
followup was available for sixty-three patients (90%), so this
group composed our study population.
2.1. Treatment. Prior to the conditioning regimen 56% of
the patients received only two lines of chemotherapy, and
44% received more than two lines. Chemotherapy and GCSF
mobilization followed by stem cell collection was used in
89% of patients, while GCSF alone followed by stem cell
collection was used in 11% of cases. The source of stem cells
was peripheral blood in all cases.
Sixty (95%) of 63 patients received BEAM (BCNU,
Etoposide, Ara-C, and Melphalan) as conditioning. One
patient received CBV (Cytoxan, BCNU, VP16), and two
patients received TEAM (Thiotepa, Etoposide, Ara-C, and
Melphalan). The median CD34 dose delivered was 5.6 ×
106/kg (1.51–12.1). All patients received routine prophylaxis
with acyclovir, ﬂuconazole, and trimethoprim/sulfamethox-
azole.
Patients had followup CT scan at day 30, and CT scan or
PET-CT scan at day 100. RECIST criteria were used to assess
response by CT scan. The majority of patients had only CT
scan for followup.
2.2. End Points. The primary end points were
(i) the rate of complete remission at day 100,
(ii) overall survival (OS),
(iii) relapse-free survival (RFS),
(iv) overall survival and RFS according to disease status
at the time of transplant, number of chemotherapy
lines, age group, and TTR.
The secondary end points were
(i) day 100 nonrelapse mortality (NRM),
(ii) incidence of grade 3-4 mucositis.
Table 1: Characteristics of 63 patients with HL who underwent au-
tologous stem cell transplantation.
Count (%)
Gender Male 38 (60.3%)
Female 25 (39.7%)
Age Adult 54 (85.7%)
Pediatric 9 (14.3%)
Number of previous
Chemotherapy lines
received
2 lines 35 (55.6%)
>2 lines 28 (44.4%)
Disease status at
transplant
Complete remission 16 (25.4%)
Responsive disease 45 (71.4%)
Stable disease 2 (3.2%)
Time to relapse
(TTR)
≤12 months 30 (48%)
>12 months 33 (52%)
Mobilization
regimen
Chemotherapy +
GCSF 57 (90.5%)
GCSF only 6 (9.5%)
Stem cell source Peripheral 63 (100%)
Stem cell dose Median (range) 5.6 ×106/kg
(1.51−12.1 ×106/kg)
Conditioning
regimen
BEAM∗ 60 (95.2%)
TEAM∗∗ 2 (3.2%)
CBV∗∗∗ 1 (1.6%)
∗BEAM: BCNU, etoposide, Ara-C, melphalan.
∗∗TEAM: thiotepa, etoposide, Ara-C, melphalan.
∗∗∗CBV: cyclophosphamide, BCNU, VP16.
2.3. Statistical Analysis. T h er a t eo fc o m p l e t er e m i s s i o na t
day 100, as well as the overall survival, and relapse-free sur-
vivalsweretheprimaryoutcomesofthisstudy.Furthermore,
day 100 nonrelapse mortality (NRM) and incidence of grade
3, 4 mucositis are secondary outcomes to be investigated in
thisstudy.Outcomecomparisonbetweengroupscategorized
by disease status at the end of treatment, number of lines of
chemotherapy, time to relapse, and age groups was carried
out. Kaplan-Meier method was used to present survival
curves. Comparison between groups in survival was carried
out using Log Rank test.
3. Results
3.1. Patients’ Characteristics. The characteristics of the 63
patients at the time of autologous stem cell transplant are
listed in Table 1.
Only 16 (25.4%) of the 63 patients were in complete
remissions (CRs) at the time of transplantation; the majority
of patients in this series had responsive disease, 45 patients
(71.4%), and 2 patients (3%) had stable disease. All patients
had successful engraftment, with a median time of 10 days
for white blood cells and 12 days for platelets engraftment.
3.1.1. Overall Survival. All 63 patients were followed with a
median follow-up time of 34.89 months. The median overallISRN Oncology 3
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Figure 1: Overall survival of 63 patients received autologous trans-
plantation for HL.
Table 2
Summary statistics
Total observed 63
Total failed 13
Total censored 50
Mean survival time
Mean survival time (survival < 40.9) 32.550
Standard deviation 2.070
Lower bound (95%) 28.492
Upper bound (95%) 36.608
Quantiles estimation
Quantile 50%
Estimate 40.600
Lower bound (95%) 27.500
Upper bound (95%)
survival was 40.6 months, with projected 3-year overall
survival of 64.6% as shown in Figure 1 and Table 2.
Theoverallsurvivalofpatientswhoreceivedtwolinesbe-
foretransplantwassigniﬁcantlybetterthanthatof thosewho
received more than two lines, 73% versus 43% (P = 0.049)
Figure 2 and Table 3. However, there was no statistically
signiﬁcant diﬀerence between those who were in complete
remission versus those with responsive disease. Also, there
was no statistical diﬀerence in the survival of children or
adults who received autologous transplant and no diﬀerence
in survival according to TTR >12 months or <12 months.
3.1.2. Relapse-Free Survival. The median RFS for the whole
group was 20 months. The projected 3-year RFS is 42.3%
Figure 3andTable 4.Exploringtheimpactofdiseasestatusat
transplant, number of lines of chemotherapy age group, and
TTR on relapse-free survival, it was found that none of these
factors signiﬁcantly aﬀected the time to relapse. It is worth
mentioning here that there was a trend for improvement in
RFS for patients who received two lines in comparison to
those who received more than two (P value = 0.095) as seen
in Figure 4 and Table 5.
3.2. Day 100 Mortality and Incidence of Grade 3-4 Mucositis.
Only three patients died in the ﬁrst 100 days (4.8%), after
transplant. The cause of death was sepsis in all of the three
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Figure 2:Overallsurvivalof63patientswithHLaccordingtonum-
ber of lines of chemotherapy received before transplantation.
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Figure 3: Relapse free-survival of 63 patients received autologous
transplantation for HL.
Table 3
Summary statistics (≤2 line)
Total observed 35
Total failed 4
Total censored 31
Quantiles estimation (≤2 line)
Quantile 50%
Estimate
Lower bound (95%)
Upper bound (95%)
Quantiles estimation (>2 lines)
Total observed 28
Total failed 9
Total censored 19
Quantile 50%
Estimate 36.100
Lower bound (95%) 23.800
Upper bound (95%) 40.600
Statistic Log-rank
P value 0.050
cases. This is comparable to the acceptable international
ﬁgures. As for grade 3-4 mucositis, its occurrence reached
50%.4 ISRN Oncology
Table 4
Summary statistics
Total observed 63
Total failed 24
Total censored 39
Quantiles estimation
Quantile 50%
Estimate
Lower bound (95%) NA
Upper bound (95%) NA
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Figure 4: Relapse-free survival of 63 patients with HL according to
number of lines of chemotherapy received before transplantation.
4. Discussion
High-dose chemotherapy with autologous stem cell trans-
plantation is a well-established potentially curative therapy
for relapsed/refractory Hodgkin’s lymphoma.
At KHCC sixty-three patients underwent high-dose
chemotherapy with autologous transplant from 2003 to
2008. At the time of transplantation 25% of patients were
in CR, and at day 100 the number rose to 57%. Prior to the
conditioning regimen, 55.6% received two lines of chemo-
therapy and 44.4% received more than two lines.
The median survival for the whole group was 40.6
months, with projected 3-year overall survival of 64.6%, and
themedianRFSwas20months,withprojected3-yearRFSof
42.3%.
These results were close to the 5-year OS and RFS pub-
lished by Engelhardt et al. [21].
Allpatientsengraftedontime.Theincidenceofgrade3-4
mucositis was 50%, and the day 100 mortality was 4.8%.
The correlation between the numbers of chemotherapy
lines received prior to conditioning and survival was statis-
tically signiﬁcant. This is consistent with some previously
published studies [15–19], although this was not shown in
the study published by Engelhardt et al. [21]. In our study
Table 5
Summary statistics (≤2 line)
Total observed 35
Total failed 11
Total censored 24
Quantiles estimation (≤2 line)
Quantile 50%
Estimate NA
Lower bound (95%)
Upper bound (95%)
Summary statistics (>2 lines)
Total observed 28
Total failed 13
Total censored 15
Quantiles estimation (>2 lines)
Quantile 50%
Estimate 10.000
Lower bound (95%) 4.600
Upper bound (95%)
Test of equality of the survival
distribution functions (DF = 1)
Statistic Log-rank
P value 0.094
there was a trend towards improvement in RFS in patients
who received two lines of chemotherapy in comparison to
those who received more than two lines, but this was not
statisticallysigniﬁcant,probablyduetothesmallsamplesize.
The disease status at the time of transplant (CR versus
RD) did not aﬀect the OS or RFS, and this is consistent with
Engelhardt et al. study [21], but contradicting other studies
[14, 17, 20]. We believe that the main reason for this is the
small sample size in our study, as there was a trend towards
improvement in patients who were in CR over those who
had RD, with P values of 0.10 and 0.15 for RFS and OS,
respectively.
There was no diﬀerence in outcome between the two age
groups in term of OS and RFS, with the caveat of the small
number of pediatric patients. There was no diﬀerence in OS
and RFS according to TTR.
5. Conclusion
We can therefore conclude from our study that the number
of chemotherapy lines received prior to the conditioning
regimen is the most important predictor of survival.
Our patients who proceeded to autologous transplanta-
tion had to have chemosensitive disease; otherwise changing
thechemotherapylinewasrecommendedincaseprogression
or no response after two cycles of therapy. This supports
the hypothesis that the tumor biology is the most important
predictor of OS, with tumors that were sensitive to the ﬁrst
line of salvage chemotherapy having a better outcome thanISRN Oncology 5
those that were not, even if the latter responded to further
salvage chemotherapy.
Relapse after autologous transplant for HL remains a
signiﬁcantproblemwithmorethan50%ofpatientsrelapsing
as projected from our study, so it is important to focus on
treatment strategies after relapse.
There is a potential durable response with reduced-
intensity allogenic transplant for HL patients relapsed after
autologous transplant as shown by the study of Peggs et al.
[22].
Novel agents like Brentuximab Vedotin are promising
with phase II studies showing response rate as high as 75%
in relapse/refractory HL. It is currently under investigation
in phase III trial for patients with HL at high risk for residual
disease following autologous stem cell transplantation [23].
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